Abstracts

Rilpivirine With Darunavir/Ritonavir: Pharmacokinetics & Safety in HIV Therapy-Naïve Patients

Background: A combination of ritonavir-boosted darunavir (DRV/rtv) and rilpivirine (RPV) could potentially form a once-daily nucleoside-sparing regime for therapy-naive treatment. RPV is subject to the boosting effect of hepatic cytochrome inhibition, and in an interaction study in healthy volunteers DRV/rtv increased RPV pharmacokinetic (PK) exposures, of a RPV 150mg daily dose, by 80 to 180%without…

A Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin

Background: Dyslipidemia is highly prevalent among patients with HIV infection and contributes to an increased risk of cardiovascular disease. Atorvastatin is a potent lipid-lowering agent and is used for prevention of cardiovascular disease. A complicating factor in the concomitant use of antiretroviral agents and statins is the occurrence of drug-drug interactions.This study was designed to…

Correlation between atazanavir concentrations clinical covariates and side effects

Background: Although significant relationships have been reported between atazanavir (ATV) trough concentrations and clinical outcome, therapeutic drug monitoring (TDM) of ATV is not routinely adopted in clinical practice. ATV plasma concentrations >150 ng/mL are currently considered the minimum level needed to achieve viral undetectability, while concentrations >800 ng/mL are associated with increased risk of hyperbilirubinemia.…

Tenofovir Diphosphate Concentration- Response Relationship for HIV Prevention in Vaginal Tissue

Background: Clinical trials with daily dosing of tenofovir (TFV) } emtricitabine have shown disparate results for HIV protection. It is still unknown what target tissue concentrations must be achieved to confer protection. Here we describe the utility of a novel ex vivo human mucosal tissue culture model to determine the tenofovir diphosphate (TFVDP) target for…

Tenofovir Concentrations and Prophylactic Effect in a Macaque Model of Rectal SHIV Transmission

Background: Non-human primate (NHP) models are essential in the development and evaluation of pre-exposure prophylaxis (PrEP) strategies, but few studies have compared concentration-effect results from the NHP model with that from human PrEP trials. The objective of this study was to estimate the tenofovir-diphosphate (TFV-DP) concentration associated with 90% efficacy (EC90) in the macaque rectal…

THE CEREBROSPINAL FLUID HIV RISK SCORE FOR ASSESSING CENTRAL NERVOUS SYSTEM HIV ACTIVITY

Background: Detectable cerebrospinal (CSF) HIV ribonucleic acid (RNA) is associated with central nervous system (CNS) complications, including neurocognitive impairment and depression. Routine monitoring of CSF HIV RNA presents a valuable key to reducing HIV CNS complications. However lumbar puncture procedures pose resource utilization challenges. We developed a prediction model to estimate the risk of detectable…

PK Study of Depot Medroxyprogesterone Acetate in HIV+ women on Lopinavir/ritonavir: ACTG 5283

Background: Little is known about use of depot medroxyprogesterone acetate (MPA) with boosted-protease inhibitors (PIs), a commonly used antiretroviral treatment regimen. Interactions with boosted PIs could lead to changes in efficacy or toxicity of any of these drugs. Methodology: We prospectively determined the effect of twice daily lopinavir (LPV) 400mg/ritonavir (RTV) 100 mg along with…

Low Bone Mineral Density Is Associated With Increased Risk of Incident Fracture in HIV+ Adults

Background: Although the prevalence of both low bone mineral density (BMD) and bone fractures are increased among HIV-infected adults compared with the general population, no study has yet characterized their causal association in the context of HIV infection. Methodology: We analyzed available dual energy X-ray absorptiometry (DEXA) values of the hip (left femoral neck) and…